Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

BLRX Relative to the S&P 500

BLRX Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the BioLineRx Ltd. (NASD:BLRX) seasonal charts above shows that a Buy Date of April 25 and a Sell Date of July 17 has resulted in a geometric average return of 0.42% above the benchmark rate of the S&P 500 Total Return Index over the past 13 years. This seasonal timeframe has shown positive results compared to the benchmark in 8 of those periods. This is a fair rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 13 years by an average of 42.64% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company’s current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has?an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues?from milestone payments under previously existing out-licensing agreements.

To download BLRX seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: BLRX